Q1 EPS Estimates for Upstream Bio Boosted by William Blair

Upstream Bio, Inc. (NASDAQ:UPB) – Investment analysts at William Blair boosted their Q1 2025 earnings per share estimates for Upstream Bio in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($0.35) for the quarter, up from their prior forecast of ($0.40). The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio’s Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($1.91) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.36) EPS, FY2028 earnings at ($1.53) EPS and FY2029 earnings at ($1.75) EPS.

Upstream Bio Stock Performance

Upstream Bio stock opened at $9.61 on Friday. The company has a fifty day simple moving average of $9.76. Upstream Bio has a 1-year low of $6.65 and a 1-year high of $29.46.

Institutional Investors Weigh In On Upstream Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new stake in Upstream Bio in the fourth quarter valued at about $25,000. US Bancorp DE acquired a new position in shares of Upstream Bio in the fourth quarter valued at about $27,000. Legal & General Group Plc acquired a new position in shares of Upstream Bio in the fourth quarter valued at about $28,000. Summit Investment Advisors Inc. acquired a new position in shares of Upstream Bio in the fourth quarter valued at about $30,000. Finally, Tower Research Capital LLC TRC acquired a new position in shares of Upstream Bio in the fourth quarter valued at about $47,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.